急性膵炎市場- 世界の産業規模、シェア、動向、機会、予測、治療別、診断別、エンドユーザー別、地域別、競合別、2020-2030年

急性膵炎の世界市場規模は2024年に51億米ドルとなり、予測期間では2030年までCAGR 5.59%で力強い成長が予測されています。

世界の急性膵炎市場は、膵臓の重篤な炎症性疾患である急性膵炎の診断、治療、管理を網羅するヘルスケア産業内のダイナミックで進化するセクターです。この市場は、ライフスタイルの変化、アルコール消費量の増加、肥満の増加など様々な要因により、近年著しい成長と変貌を遂げており、これらすべてが急性膵炎の世界の有病率の増加に寄与しています。NLMによる2022年11月の記事によると、急性膵炎は米国で最も一般的な消化器疾患であり、入院の主な原因となっています。さらに、2022年7月のMedRxivの論文によると、胆石症による外来受診は約220万件、救急外来受診は110万件、入院退院は61.5万件でした。同じ情報源は、女性が男性よりも胆石を発症しやすいことを指摘しています。この市場の主な促進要因のひとつは、急性膵炎の認知度の向上と早期診断であり、そのため画像検査や血液検査など、病態を正確に特定し重症度を評価するための診断検査の需要が急増しています。

市場促進要因

ライフスタイルのパターンとリスク要因の変化

主な市場課題

高い治療費

主な市場動向

低侵襲手術の進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の急性膵炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（点滴、栄養補給、鎮痛剤、内視鏡的逆行性胆道膵管造影（ERCP）、その他の治療）
  • 診断（画像検査、臨床検査）
  • エンドユーザー別（病院・診療所、外来診療センター、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 治療別
  • 診断別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の急性膵炎市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別
  • 診断別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の急性膵炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の急性膵炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の急性膵炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの急性膵炎市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • エジプト

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の急性膵炎市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• SCM Lifescience
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Acute Pancreatitis Market was valued at USD 5.10 billion in 2024 and is anticipated to project robust growth in the forecast period with a CAGR of 5.59% through 2030. The Global Acute Pancreatitis Market is a dynamic and evolving sector within the healthcare industry that encompasses the diagnosis, treatment, and management of acute pancreatitis, a severe inflammatory condition of the pancreas. This market has witnessed significant growth and transformation in recent years due to various factors, including changing lifestyle patterns, increasing alcohol consumption, and a rising incidence of obesity, all of which are contributing to the growing prevalence of acute pancreatitis worldwide. According to a November 2022 article by the NLM, acute pancreatitis is the most common gastrointestinal condition and the leading cause of hospitalization in the United States. Additionally, a July 2022 MedRxiv article reported that gallstone disease accounted for approximately 2.2 million ambulatory care visits, 1.1 million emergency department visits, and 615,000 hospital discharges. The same source noted that women are more likely to develop gallstones than men. One of the key drivers of this market is the increasing awareness and early diagnosis of acute pancreatitis, which has led to a surge in demand for diagnostic tests, such as imaging studies and blood tests, to accurately identify and assess the severity of the condition.

Key Market Drivers

Changing Lifestyle Patterns and Risk Factors

The global acute pancreatitis market is experiencing significant growth, in large part due to changing lifestyle patterns and the associated risk factors that are driving the increasing prevalence of this painful and potentially life-threatening condition. Modern lifestyles characterized by unhealthy dietary habits, high alcohol consumption, and a rising global obesity epidemic have created a perfect storm of risk factors that are contributing to the surge in acute pancreatitis cases worldwide. For instance, in December 2022, St. Jude Children's Research Hospital, in partnership with CalciMedica, Inc., initiated a Phase I/II clinical trial to evaluate the safety and effectiveness of CM4620 in children and young adults with asparaginase-induced acute pancreatitis. Also, in October 2022, Regeneron Pharmaceuticals initiated a Phase II clinical trial to assess the efficacy and safety of evinacumab in patients with severe hypertriglyceridemia to prevent recurrent acute pancreatitis.

Key Market Challenges

High Treatment Costs

One of the primary drivers of high treatment costs for acute pancreatitis is the need for hospitalization. Severe cases of acute pancreatitis often require extended stays in the hospital, where patients receive specialized care, including pain management, nutritional support, and monitoring for complications. These extended hospital stays can result in exorbitant medical bills, particularly in countries with private healthcare systems. Early and accurate diagnosis of acute pancreatitis is critical for effective management. However, diagnostic tests, such as computed tomography (CT) scans, magnetic resonance imaging (MRI), and blood work, can be expensive. The cost of these diagnostic procedures can escalate the overall financial burden on patients and healthcare systems. In cases of severe acute pancreatitis, surgical interventions may be necessary to address complications like infected pancreatic necrosis or pseudocysts. Surgery, especially when performed laparoscopically or using minimally invasive techniques, can be costly and contribute significantly to the overall treatment expenses.

Key Market Trends

Advancements in Minimally Invasive Surgery

Advancements in minimally invasive surgical techniques have emerged as a pivotal trend in the global acute pancreatitis market, revolutionizing the treatment landscape for this severe pancreatic condition. Minimally invasive surgery (MIS), which includes procedures like laparoscopy and endoscopy, offers significant benefits such as reduced postoperative pain, shorter hospital stays, and faster patient recovery times. These advantages have not only improved patient outcomes but also contributed to the growth of the acute pancreatitis market in several ways.

One of the primary ways in which MIS is boosting the market is by enhancing patient comfort and overall satisfaction. Traditional open surgeries for acute pancreatitis often involve larger incisions and more extensive tissue disruption, leading to prolonged postoperative pain and recovery periods. In contrast, minimally invasive approaches involve smaller incisions, resulting in less pain, reduced scarring, and shorter hospitalization. This patient-centric focus has made MIS an attractive option for both patients and healthcare providers, driving its adoption and contributing to market growth.

Key Market Players

• SCM Lifescience
• GNT Pharma Co
• Baxter International Inc.
• B. Braun Melsungen AG
• General Electric Company
• Medtronic Plc
• Boston Scientific Corporation
• Fresenius Kabi USA
• McNeil Consumer Healthcare
• Sun BioPharma

Report Scope:

In this report, the Global Acute Pancreatitis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Acute Pancreatitis Market, By Treatment:

• Intravenous Fluid
• Nutritional Support
• Analgesics
• Endoscopic Retrograde Cholangiopancreatography (ERCP)
• Other treatments

Acute Pancreatitis Market, By Diagnosis:

• Imaging tests
• Laboratory Tests

Acute Pancreatitis Market, By End-User:

• Hospitals & Clinics
• Ambulatory care Centers
• Others

Acute Pancreatitis Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Acute Pancreatitis Market.

Available Customizations:

Global Acute Pancreatitis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Acute Pancreatitis Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Treatment (Intravenous Fluid, Nutritional Support, Analgesics, Endoscopic Retrograde Cholangiopancreatography (ERCP), Other treatments)
  • 4.2.2. By Diagnosis (Imaging tests, Laboratory Tests)
  • 4.2.3. By End-User (Hospitals & Clinics, Ambulatory care Centers, Others)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Treatment
  • 4.3.2. By Diagnosis
  • 4.3.3. By End-User
  • 4.3.4. By Region

5. Asia Pacific Acute Pancreatitis Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Treatment
  • 5.2.2. By Diagnosis
  • 5.2.3. By End-User
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Acute Pancreatitis Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Treatment
      • 5.3.1.2.2. By Diagnosis
      • 5.3.1.2.3. By End-User
  • 5.3.2. India Acute Pancreatitis Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Treatment
      • 5.3.2.2.2. By Diagnosis
      • 5.3.2.2.3. By End-User
  • 5.3.3. Australia Acute Pancreatitis Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Treatment
      • 5.3.3.2.2. By Diagnosis
      • 5.3.3.2.3. By End-User
  • 5.3.4. Japan Acute Pancreatitis Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Treatment
      • 5.3.4.2.2. By Diagnosis
      • 5.3.4.2.3. By End-User
  • 5.3.5. South Korea Acute Pancreatitis Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Treatment
      • 5.3.5.2.2. By Diagnosis
      • 5.3.5.2.3. By End-User

6. Europe Acute Pancreatitis Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Treatment
  • 6.2.2. By Diagnosis
  • 6.2.3. By End-User
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Acute Pancreatitis Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Treatment
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By End-User
  • 6.3.2. Germany Acute Pancreatitis Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Treatment
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By End-User
  • 6.3.3. Spain Acute Pancreatitis Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Treatment
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By End-User
  • 6.3.4. Italy Acute Pancreatitis Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Treatment
      • 6.3.4.2.2. By Diagnosis
      • 6.3.4.2.3. By End-User
  • 6.3.5. United Kingdom Acute Pancreatitis Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Treatment
      • 6.3.5.2.2. By Diagnosis
      • 6.3.5.2.3. By End-User

7. North America Acute Pancreatitis Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Treatment
  • 7.2.2. By Diagnosis
  • 7.2.3. By End-User
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Acute Pancreatitis Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Treatment
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By End-User
  • 7.3.2. Mexico Acute Pancreatitis Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Treatment
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By End-User
  • 7.3.3. Canada Acute Pancreatitis Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Treatment
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By End-User

8. South America Acute Pancreatitis Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Treatment
  • 8.2.2. By Diagnosis
  • 8.2.3. By End-User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Acute Pancreatitis Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Treatment
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By End-User
  • 8.3.2. Argentina Acute Pancreatitis Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Treatment
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By End-User
  • 8.3.3. Colombia Acute Pancreatitis Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Treatment
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By End-User

9. Middle East and Africa Acute Pancreatitis Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Treatment
  • 9.2.2. By Diagnosis
  • 9.2.3. By End-User
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Acute Pancreatitis Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Treatment
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By End-User
  • 9.3.2. Saudi Arabia Acute Pancreatitis Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Treatment
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By End-User
  • 9.3.3. UAE Acute Pancreatitis Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Treatment
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By End-User
  • 9.3.4. Egypt Acute Pancreatitis Market Outlook
    • 9.3.4.1. Market Size & Forecast
      • 9.3.4.1.1. By Value
    • 9.3.4.2. Market Share & Forecast
      • 9.3.4.2.1. By Treatment
      • 9.3.4.2.2. By Diagnosis
      • 9.3.4.2.3. By End-User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Acute Pancreatitis Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. SCM Lifescience
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. GNT Pharma Co
• 14.3. Baxter International Inc.
• 14.4. B. Braun Melsungen AG
• 14.5. General Electric Company
• 14.6. Medtronic Plc
• 14.7. Boston Scientific Corporation
• 14.8. Fresenius Kabi USA
• 14.9. McNeil Consumer Healthcare
• 14.10. Sun BioPharma

15. Strategic Recommendations

16. About Us & Disclaimer